-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In most people’s previous knowledge, HPV vaccines prevent cervical cancer and are exclusive to women
Recently, research institutes from the United States, China, Germany and many other countries published the title "The Lancet · Infectious Disease Lancet · Infectious Disease Efficacy, immunogenicity, and safety of " in the internationally renowned journal "The Lancet · Infectious Diseases ".
This research started in 2004 and is divided into basic research and long-term follow-up research
Study design and participant process Before the quadrivalent HPV vaccination, the baseline characteristics of the participants in the early vaccination group and the supplement vaccine group were basically similar, and the seropositivity rates for HPV6, 11, 16, and 18 and PCR positive rates were similar
Reduced incidence of HPV-related external genital and anal diseases in 16-26-year-old vaccinated men who participated in the long-term follow-up study
Long-term follow-up study vaccination quadrivalent HPV vaccine MSM with HPV6,11,16 and 18 related cumulative incidence of anal intraepithelial neoplasia and anal cancer last look at the immunogenicity of male HPV vaccination in the early In the vaccination group, anti-HPV6, 11, 16, and 18 antibodies lasted 120 months after the first vaccination (Figure 3)
From the 1st day of the basic study to the 10th year of the long-term follow-up study, the anti-HPV6, 11, 16 and 18 antibody titers of the participants in the early vaccine group in the competitive Luminex immunoassay.
End
1] Efficacy, immunogenicity, and Safety of Vaccine A of HPV quadrivalent inmen: AN Results of Open-label, Long-Term Extension of A randomized, Placebo-Controlled, Trial Phase.
3
in this message
Recently, research institutes from the United States, China, Germany and many other countries published the title "The Lancet · Infectious Disease Lancet · Infectious Disease Efficacy, immunogenicity, and safety of " in the internationally renowned journal "The Lancet · Infectious Diseases ".
This research started in 2004 and is divided into basic research and long-term follow-up research
Study design and participant process Before the quadrivalent HPV vaccination, the baseline characteristics of the participants in the early vaccination group and the supplement vaccine group were basically similar, and the seropositivity rates for HPV6, 11, 16, and 18 and PCR positive rates were similar
Reduced incidence of HPV-related external genital and anal diseases in 16-26-year-old vaccinated men who participated in the long-term follow-up study
In further analysis, the researchers used the Kaplan-Meier method to evaluate the cumulative incidence of anal intraepithelial neoplasia and anal cancer associated with HPV6, 11, 16, or 18 in the early vaccination group and the supplementary vaccine group in MSM.
Long-term follow-up study vaccination quadrivalent HPV vaccine MSM with HPV6,11,16 and 18 related cumulative incidence of anal intraepithelial neoplasia and anal cancer last look at the immunogenicity of male HPV vaccination in the early In the vaccination group, anti-HPV6, 11, 16, and 18 antibodies lasted 120 months after the first vaccination (Figure 3)
From the 1st day of the basic study to the 10th year of the long-term follow-up study, the anti-HPV6, 11, 16 and 18 antibody titers of the participants in the early vaccine group in the competitive Luminex immunoassay.
End
Reference materials:
Reference materials:[1] Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine inmen: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial
[.1] Efficacy, immunogenicity, and Safety of Vaccine A of HPV quadrivalent inmen: AN Results of Open-label, Long-Term Extension of A randomized, Placebo-Controlled, Trial Phase.
3
in this message
